


IN THE CLAIMS

Please amend the claims as follows:

1.- (Currently Amended) ~~Sulfonamide compounds~~ A sulfonamide of general formula (Ia),



(Ia)

wherein

$R^1$  represents a  $-NR^7R^8$  radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$ , identical or different, each represent hydrogen, halogen, cyano, nitro, a saturated or unsaturated, linear or branched aliphatic radical, a linear or branched alkoxy radical, a linear or branched alkylthio radical, hydroxy, trifluoromethyl, a saturated or unsaturated cycloaliphatic radical, an alkylcarbonyl radical, a phenylcarbonyl or a  $-NR^9R^{10}$  group,

$R^7$  and  $R^8$ , identical or different, each represent hydrogen or a saturated or unsaturated, optionally at least mono-substituted linear or branched aliphatic radical,

with the proviso that  $R^8$  and  $R^9$  are not hydrogen at the same time, and if one of them,  $R^8$  or  $R^9$ , is a saturated or unsaturated, linear or branched, optionally at least mono-substituted  $C_1$ - $C_4$  aliphatic radical, the other one is a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical with at least five carbon atoms,

or

$R^7$  and  $R^8$ , together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

$R^9$  and  $R^{10}$ , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

or

$R^9$  and  $R^{10}$ , together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

A and B, identical or different, each represent a saturated or unsaturated, linear or branched, ~~optionally at least mono-substituted~~ aliphatic radical, optionally at least mono-substituted

or

A and B, together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic, ~~optionally at least mono-substituted~~ cycloalkyl ring,

optionally at least mono-substituted





and

n is 0,


a stereoisomer thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a pharmaceutically acceptable salt thereof, or mixtures thereof optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate or in form of a mixture of at least two of their stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding physiologically acceptable salt thereof or a corresponding solvate thereof.

2. (Currently Amended) The ~~compounds~~ compound according to claim 1, ~~characterized in that wherein~~ R<sup>1</sup> represents a -NR<sup>7</sup>R<sup>8</sup> radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing 5- or 6-membered cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system, whereby the rings of the ring system are 5- or 6-membered;

preferably a NR<sup>7</sup>R<sup>8</sup> radical or a radical chosen from the group consisting of



and



~~wherein, if present, the dotted line represents an optional chemical bond, and R<sup>19</sup> represents hydrogen, a linear or branched C<sub>1</sub>-C<sub>6</sub> alkyl radical or a benzyl radical, preferably hydrogen or a C<sub>1</sub>-C<sub>2</sub> alkyl radical.~~

- 3.- (Currently Amended) The ~~compounds~~ compound according to claim 1 ~~or 2~~, characterized in that ~~wherein~~ R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup>, identical or different, each represent hydrogen, F, Cl, Br, cyano, nitro, a linear or branched C<sub>1-6</sub> alkyl radical, a linear or branched C<sub>2-6</sub> alkenyl radical, a linear or branched C<sub>2-6</sub> alkynyl radical, a linear or branched C<sub>1-6</sub> alkoxy, a linear or branched C<sub>1-6</sub> alkylthio, hydroxy, trifluoromethyl, a saturated or unsaturated C<sub>3-8</sub> cycloaliphatic radical, a linear or branched C<sub>1-6</sub> alkylcarbonyl radical, phenylcarbonyl or an -NR<sup>9</sup>R<sup>10</sup> group;

~~preferably H, F, Cl, NO<sub>2</sub>, NH<sub>2</sub> or a C<sub>1-2</sub> alkyl radical.~~


- 4.- (Currently Amended) The ~~compounds~~ compound according to ~~one or more of claims 1 to 3~~, characterized in that claim 1, wherein R<sup>7</sup> and R<sup>8</sup>, identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C<sub>1-10</sub> alkyl radical, a linear or branched, optionally at least mono-substituted, C<sub>2-10</sub> alkenyl radical, or a linear or branched, optionally at least mono-substituted, C<sub>2-10</sub> alkynyl radical or

R<sup>7</sup> and R<sup>8</sup>, together with the bridging nitrogen form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing 5- or 6-membered heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at

least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system, whereby the rings of the ring system are 5- 6- or 7-membered.

- 5.- (Currently Amended) The ~~compounds~~ compound according to claim 4, characterized ~~in that~~ wherein  $R^7$  and  $R^8$ , identical or different, each represent hydrogen or a linear or branched  $C_{1-10}$  alkyl radical or

$R^7$  and  $R^8$ , together with the bridging nitrogen atom form a radical chosen from the group consisting of




wherein  $R^{20}$ , if present, is hydrogen, a linear or branched  $C_1-C_6$  alkyl radical or a benzyl radical, ~~preferably hydrogen, or a  $C_1-C_2$  alkyl radical.~~

- 6.- (Currently Amended) The ~~compounds~~ compound according to ~~one or more of claims 1 to 5~~ claim 1, characterized in that wherein  $R^9$  and  $R^{10}$ , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted  $C_1$ - $C_{10}$  alkyl radical, a linear or branched, optionally at least mono-substituted  $C_2$ - $C_{10}$  alkenyl radical or a linear or branched, optionally at least mono-substituted  $C_2$ - $C_{10}$  alkynyl radical or

$R^9$  and  $R^{10}$ , together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing 5- or 6-membered heterocyclic ring, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system whereby the rings of the ring system are 5- 6- or 7-membered.

- 7.- (Currently Amended) The ~~compounds~~ compound according to claim 6, characterized ~~in that~~ wherein  $R^9$  and  $R^{10}$ , identical or different, each represent hydrogen or a linear or branched  $C_1$ - $C_{10}$  alkyl radical, or

$R^9$  and  $R^{10}$ , together with the bridging nitrogen atom form a radical chosen from a group consisting of



wherein  $R^{20}$ , if present, is hydrogen, a linear or branched  $C_1$ - $C_6$  alkyl radical or a benzyl radical, ~~preferably hydrogen, or a  $C_1$ - $C_2$  alkyl radical.~~

- 8.- (Currently Amended) The ~~compounds~~ compound according to ~~one or more of claims 1-7, characterized in that~~ claim 1, wherein A and B, identical or different, each represent a linear or branched  $C_1$ - $C_6$  alkyl radical, a linear or branched  $C_2$ - $C_6$  alkenyl radical or a linear or branched  $C_2$ - $C_6$  alkynyl radical,

~~preferably a linear or branched  $C_1$ - $C_6$  alkyl radical, or~~

A and B, together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic, optionally at least mono-substituted cycloalkyl ring,

~~preferably a  $C_3$ - $C_8$  cycloalkyl ring,~~

~~more preferably a cyclohexyl ring.~~

- 9.- (Currently Amended) The ~~compounds~~ compound to ~~one or more of claims 1-8, characterized in that the compound is~~ claim 1, which is selected from a group consisting of

[1] 1-Cyclohexanesulfonyl-3-(1-methyl-1,2,3,6-tetrahydropyridine-4-yl)-5-nitro-1H-indole,


[2] 5-Chloro-1-cyclohexanesulfonyl-3-(1-methyl-1,2,3,6-tetrahydropyridine-4-yl)-1H-indole,

[3] 5-Amino-1-cyclohexanesulfonyl-3-(1-methyl-1,2,3,6-tetrahydropyridine-4-yl)-1H-indole, ~~and~~

[4] 1-Cyclohexanesulfonyl-5-fluoro-3-(1,2,3,5,8,8a-hexahydro-indolizine-7-yl)-1H-indole hydrochloride,

~~and their corresponding salts and solvates~~ a salt thereof, and a solvate thereof.

10.- (Withdrawn- Currently Amended) ~~Sulfonamide compounds~~ A sulfonamide compound of general formula (Ib),



(Ib)

wherein

$R^1$  is a  $-NR^7R^8$  radical,

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$ , identical or different, each represent hydrogen, halogen, cyano, nitro, a saturated or unsaturated, linear or branched aliphatic radical, a linear or branched alkoxy radical, a linear or branched alkylthio radical, hydroxy, trifluoromethyl, a saturated or unsaturated cycloaliphatic radical, an alkylcarbonyl radical, a phenylcarbonyl or a  $-NR^9R^{10}$  group,

$R^7$  and  $R^8$ , identical or different, each represent hydrogen or a saturated or



unsaturated, optionally at least mono-substituted linear or branched C<sub>1-4</sub> aliphatic radical,

R<sup>9</sup> and R<sup>10</sup>, identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

or

R<sup>9</sup> and R<sup>10</sup>, together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

A and B, identical or different, each represent a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical

or

A and B, together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic, optionally at least mono-substituted cycloalkyl ring,

and

n is 0;

a stereoisomer thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a pharmaceutically acceptable salt thereof, or mixtures thereof optionally in

~~form of one of its stereoisomers, preferably enantiomers or diastereomers, their racemate or in form of a mixture of at least two of their stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding physiologically acceptable salt thereof or a corresponding solvate thereof.~~

- 11.- (Withdrawn-Currently Amended) The ~~compounds~~ compound according to claim 10, ~~characterized in that~~ wherein  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$ , identical or different, each represent hydrogen, F, Cl, Br, cyano, nitro, a linear or branched  $C_1$ - $C_6$  alkyl radical, a linear or branched  $C_2$ - $C_6$  alkenyl radical, a linear or branched  $C_2$ - $C_6$  alkynyl radical, a linear or branched  $C_1$ - $C_6$ -alkoxy, a linear or branched  $C_1$ - $C_6$ -alkylthio, hydroxy, trifluoromethyl, a saturated or unsaturated  $C_3$ - $C_8$  cycloaliphatic radical, a linear or branched  $C_1$ - $C_6$ -alkylcarbonyl radical, phenylcarbonyl or an  $-NR^9R^{10}$  group, preferably H, F, Cl,  $NO_2$ ,  $NH_2$  or a  $C_1$ - $C_2$  alkyl radical.
- 12.- (Withdrawn-Currently Amended) The ~~compounds~~ compound according to claim 10 or 11, ~~characterized in that~~ wherein  $R^7$  and  $R^8$ , identical or different, wherein  $R^7$  and  $R^8$ , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted  $C_1$ - $C_4$  alkyl radical,


~~preferably hydrogen or a C<sub>1</sub>-C<sub>2</sub> alkyl radical~~, with the proviso that R<sup>7</sup> and R<sup>8</sup> are not hydrogen at the same time.

- 13.- (Withdrawn-Currently Amended) The ~~compounds~~ compound according to ~~one or more of claims 10 to 12~~ claim 10, characterized in that R<sup>9</sup> and R<sup>10</sup>, identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C<sub>1</sub>-C<sub>10</sub> alkyl radical, a linear or branched, optionally at least mono-substituted C<sub>2</sub>-C<sub>10</sub> alkenyl radical, or a linear or branched, optionally at least mono-substituted C<sub>2</sub>-C<sub>10</sub> alkynyl radical or

R<sup>9</sup> and R<sup>10</sup>, together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing 5- or 6-membered heterocyclic which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system, whereby the rings of the ring system are 5- 6- or 7-membered.

- 14.- (Withdrawn-Currently Amended) The ~~compounds~~ compound according to claim 13, ~~characterized in that~~ wherein R<sup>9</sup> and R<sup>10</sup>, identical or different, each represent hydrogen or a linear or branched C<sub>1</sub>-C<sub>10</sub> alkyl radical, or

R<sup>9</sup> and R<sup>10</sup>, together with the bridging nitrogen atom form a radical chosen from a group consisting of




wherein R<sup>20</sup>, if present, represents hydrogen, a linear or branched C<sub>1</sub>-C<sub>6</sub> alkyl radical or a benzyl radical, ~~preferably hydrogen, or a C<sub>1</sub>-C<sub>2</sub> alkyl radical.~~

- 15.- (Currently Amended) The ~~compounds~~ compound according to ~~one or more of claims 10 to 14~~ claim 10, ~~characterized in that wherein~~ A and B, together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic, optionally at least mono-substituted cycloalkyl ring,

~~preferably a C<sub>3</sub>-C<sub>8</sub> cycloalkyl ring,~~


~~more preferably a cyclohexyl ring.~~

- 16.- (Currently Amended) A process for obtaining a sulfonamide ~~derivative~~ compound of general formula (Ia) ~~and/or (Ib)~~, ~~according to one or more of claims 1 to 15~~ according to claim 1, ~~characterized in that wherein~~ at least one compound of general formula (II), or ~~one of its suitably protected derivatives~~ a protected compound thereof,



(II)

wherein A and B have the meaning according to ~~one or more of claims 1 to 15~~ claim 1 and X is ~~an acceptable a~~ leaving group, ~~preferably an halogen atom, more preferably chlorine,~~ is reacted with at least one substituted indole of general formula (III)



(III)

wherein R<sup>1</sup>-R<sup>6</sup> and n have the meaning according to ~~one or more of claims 1 to 15~~ claim 1, or ~~one of their suitable a~~ protected derivatives compound thereof, and, if necessary, the protective groups are removed.

- 17.- (Currently Amended) A process for obtaining a sulfonamide derivative compound of general formula (Ia) ~~and/or (Ib)~~ according to ~~one or more of claims 1 to 15~~ claim 1, wherein one or more substituents R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> or R<sup>6</sup> ~~represent~~ represent a nitro group, ~~characterized in that~~ and wherein a sulfonamide derivative compound of ~~corresponding~~ general formula (Ia) ~~and/or (Ib)~~ is reduced to a sulfonamide derivative compound of corresponding general formula (Ia) ~~and/or (Ib)~~, wherein one or more substituents R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> or R<sup>6</sup> represent an amino group.
- 18.- (Currently Amended) A process for preparing ~~the salts, preferably the physiologically acceptable salts of the compounds of general~~ a salt of the compound of formula (Ia) ~~and/or (Ib), according to one or more of claims 1 to 15, consisting of~~ according to claim 1, the process comprising reacting at least one compound of the general formula (Ia) ~~and/or at least one compound of the general formula (Ib)~~ with a mineral acid or organic acid in a ~~suitable~~ solvent to form the salt of the compound of formula (Ia).

- 19.- (Currently Amended) A ~~medicament~~ composition comprising at least one compound according to ~~one or more of claims 1 to 9 and optionally to claim 1 and~~ one or more pharmacologically acceptable excipients.
- 20.- (Cancelled).
21. - (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for~~ A method of regulating a 5-HT<sub>6</sub> receptor regulation in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to regulate a 5 HT<sub>6</sub> receptor in the subject.
- 22.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of a~~ A method of treating a disorder or disease related to food intake in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disorder or disease in the subject.
- 23.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the regulation of~~ A method for regulating appetite in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to regulate appetite in the subject.
- 24.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the maintenance, increase or~~

~~reduction of~~ A method for regulating body weight in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to regulate body weight in the subject.

25.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of~~ A method of treating obesity in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat obesity in the subject.

26.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of~~ A method of treating bulimia in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat bulimia in the subject.

27.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament the prophylaxis and/or treatment of~~ A method for treating anorexia in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat anorexia in the subject.

28.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of~~ A method for treating cachexia in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat cachexia in the subject.

- 29.- ~~(Currently Amended) The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of~~ A method for treating type II diabetes (non-insulin-dependent diabetes mellitus), preferably type II diabetes caused by obesity in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat type II diabetes in the subject.
- 30.- ~~(Currently Amended) The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the manufacture of a medicament for the prophylaxis and/or treatment of~~ A method of treating a gastrointestinal tract disorder disorders in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disorder in the subject.
- 31.- ~~(Currently Amended) The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of~~ A method for treating irritable bowel syndrome in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat irritable bowel syndrome in the subject.
- 32.- ~~(Currently Amended) The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of~~ A method for treating anxiety in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat anxiety in the subject.



- 33.- ~~(Currently Amended) The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of~~ A method for treating depression in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat depression in the subject.
- 34.- ~~(Currently Amended) The use of at least one compound according to one more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of bipolar disorders~~ A method for treating bipolar disorder in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disorder in the subject.
35. - ~~(Currently Amended) The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of~~ A method for treating cognitive memory disorder disorders in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disorder in the subject.
- 36.- ~~(Currently Amended) The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of~~ A method for treating senile dementia processes in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the senile dementia process in the subject.
- 37.- ~~(Currently Amended) The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of~~ A method for treating Alzheimer's Disease in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disease in the subject.

- 38.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of~~ A method for treating Parkinson's Disease in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disease in the subject.
- 39.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of~~ A method for treating Huntington's Disease in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disease in the subject.
- 40.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of~~ A method for treating Multiple Sclerosis in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the multiple sclerosis in the subject.
- 41.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of dementias~~ A method for treating dementia in which a cognitive deficit predominates in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the dementia in the subject.
- 42.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or~~

- treatment of A method for treating psychosis in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat psychosis in the subject.
- 43.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of~~ A method for treating infantile hyperkinesia (ADHD, attention deficit/hyperactivity disorder) in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat infantile hyperkinesia in the subject.
- 44.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of disorders~~ A method for treating a disorder of the central nervous system in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat the disorder in the subject.
- 45.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of~~ A method for treating schizophrenia in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to treat schizophrenia in the subject.
- 46.- (Currently Amended) ~~The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for cognitive enhancement~~ A method of enhancing cognitive ability in a subject in need thereof, the method comprising administering at least one compound according to claim 1 in an amount sufficient to enhance cognitive ability in the subject.

47. (Currently Amended) A ~~medicament~~ composition comprising at least one compound according to ~~one or more of claims 9 to 15~~ claim 9 and optionally at least one or more of pharmacologically acceptable excipients.

48.- (Cancelled)

49.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for 5-HT<sub>6</sub> receptor regulation.

50.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 9 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of a disorder or disease related to food intake.

51.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the regulation of appetite.

52.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the maintenance, increase or reduction of body weight.

53.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of obesity.

- 54.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of bulimia.
- 55.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of anorexia.
- 56.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of cachexia.
- 57.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of type II diabetes (non-insulin-dependent diabetes mellitus), preferably type II diabetes caused by obesity.
- 58.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of gastrointestinal tract disorders.
- 59.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of irritable bowel syndrome.

- 60.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of anxiety.
- 61.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of depression.
- 62.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of bipolar disorders.
- 63.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of cognitive memory disorders.
- 64.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of senile dementia processes.
- 65.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of Alzheimer's Disease.


- 66.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of Parkinson's Disease.
- 67.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of Huntington's Disease.
- 68.- The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of Multiple Sclerosis.
- 69.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of dementias in which a cognitive deficit predominates.
- 70.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of psychosis.
- 71.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder).

72.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of the central nervous system.

73.- (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for the prophylaxis and/or treatment of schizophrenia.

74. - (Withdrawn) The use of at least one compound according to ~~one or more of claims 10 to 15~~ claim 10 for the manufacture of a medicament for cognitive enhancement.

75. (New) The compound according to claim 1, wherein  $R^1$  represents a  $NR^7R^8$  radical or a radical chosen from the group consisting of



wherein, if present, the dotted line represents an optional chemical bond, and  $R^{19}$  represents hydrogen, a linear or branched  $C_1$ - $C_6$  alkyl radical or a benzyl radical, preferably hydrogen or a  $C_1$ - $C_2$  alkyl radical.

76. (New) The compound according to claim 1, wherein  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$ , identical or different, each represent H, F, Cl,  $NO_2$ ,  $NH_2$  or a  $C_{1-2}$  alkyl radical.